Meinolf Thiemann - Search Results

Year	Number of Results
2002	1
2003	2
2006	2
2008	1
2009	4
2010	1
2012	1
2013	1
2015	1
2016	1
2018	2
2019	3
2023	1
2024	0

1

The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy.

Frankish J, Mukherjee D, Romano E, Billian-Frey K, Schröder M, Heinonen K, Merz C, Redondo Müller M, Gieffers C, Hill O, Thiemann M, Honeychurch J, Illidge T, Sykora J. Frankish J, et al. Among authors: thiemann m. Front Immunol. 2023 May 26;14:1160116. doi: 10.3389/fimmu.2023.1160116. eCollection 2023. Front Immunol. 2023. PMID: 37304285 Free PMC article.

2

3D Cellular Architecture Modulates Tyrosine Kinase Activity, Thereby Switching CD95-Mediated Apoptosis to Survival.

Gülcüler Balta GS, Monzel C, Kleber S, Beaudouin J, Balta E, Kaindl T, Chen S, Gao L, Thiemann M, Wirtz CR, Samstag Y, Tanaka M, Martin-Villalba A. Gülcüler Balta GS, et al. Among authors: thiemann m. Cell Rep. 2019 Nov 19;29(8):2295-2306.e6. doi: 10.1016/j.celrep.2019.10.054. Cell Rep. 2019. PMID: 31747602 Free article.

3

HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.

Richards DM, Marschall V, Billian-Frey K, Heinonen K, Merz C, Redondo Müller M, Sefrin JP, Schröder M, Sykora J, Fricke H, Hill O, Gieffers C, Thiemann M. Richards DM, et al. Among authors: thiemann m. J Immunother Cancer. 2019 Jul 19;7(1):191. doi: 10.1186/s40425-019-0671-4. J Immunother Cancer. 2019. PMID: 31324216 Free PMC article.

4

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.

Hanke N, Kunz C, Thiemann M, Fricke H, Lehr T. Hanke N, et al. Among authors: thiemann m. Pharmaceutics. 2019 Apr 1;11(4):152. doi: 10.3390/pharmaceutics11040152. Pharmaceutics. 2019. PMID: 30939793 Free PMC article.

5

A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity.

Thiemann M, Richards DM, Heinonen K, Kluge M, Marschall V, Merz C, Redondo Müller M, Schnyder T, Sefrin JP, Sykora J, Fricke H, Gieffers C, Hill O. Thiemann M, et al. Front Oncol. 2018 Sep 19;8:387. doi: 10.3389/fonc.2018.00387. eCollection 2018. Front Oncol. 2018. PMID: 30298117 Free PMC article.

6

The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.

Merz C, Sykora J, Marschall V, Richards DM, Heinonen K, Redondo Müller M, Thiemann M, Schnyder T, Fricke H, Hill O, Gieffers C. Merz C, et al. Among authors: thiemann m. J Immunother. 2018 Nov/Dec;41(9):385-398. doi: 10.1097/CJI.0000000000000246. J Immunother. 2018. PMID: 30273198

7

Peripheral monocytes are functionally altered and invade the CNS in ALS patients.

Zondler L, Müller K, Khalaji S, Bliederhäuser C, Ruf WP, Grozdanov V, Thiemann M, Fundel-Clemes K, Freischmidt A, Holzmann K, Strobel B, Weydt P, Witting A, Thal DR, Helferich AM, Hengerer B, Gottschalk KE, Hill O, Kluge M, Ludolph AC, Danzer KM, Weishaupt JH. Zondler L, et al. Among authors: thiemann m. Acta Neuropathol. 2016 Sep;132(3):391-411. doi: 10.1007/s00401-016-1548-y. Epub 2016 Feb 24. Acta Neuropathol. 2016. PMID: 26910103

8

Infiltration of circulating myeloid cells through CD95L contributes to neurodegeneration in mice.

Gao L, Brenner D, Llorens-Bobadilla E, Saiz-Castro G, Frank T, Wieghofer P, Hill O, Thiemann M, Karray S, Prinz M, Weishaupt JH, Martin-Villalba A. Gao L, et al. Among authors: thiemann m. J Exp Med. 2015 Apr 6;212(4):469-80. doi: 10.1084/jem.20132423. Epub 2015 Mar 16. J Exp Med. 2015. PMID: 25779632 Free PMC article.

9

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.

Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R, Fischer C, Branschädel M, Abhari BA, Hohenberger P, Fulda S, Fricke H, Hill O. Gieffers C, et al. Among authors: thiemann m. Mol Cancer Ther. 2013 Dec;12(12):2735-47. doi: 10.1158/1535-7163.MCT-13-0323. Epub 2013 Oct 7. Mol Cancer Ther. 2013. PMID: 24101228

10

Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients.

Tuettenberg J, Seiz M, Debatin KM, Hollburg W, von Staden M, Thiemann M, Hareng B, Fricke H, Kunz C. Tuettenberg J, et al. Among authors: thiemann m. Int Immunopharmacol. 2012 May;13(1):93-100. doi: 10.1016/j.intimp.2012.03.004. Epub 2012 Mar 21. Int Immunopharmacol. 2012. PMID: 22446296 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

20 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year